Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors

Nuclear Medicine and Biology

Volumn 39, Issue 1, 2012, Pages 3-13

  Beckford Vera, Denis R ^a   Eigner, Sebastian ^a   Henke, Katerina Eigner ^a   Lebeda, Ondrej ^a   Melichar, Frantisek ^a   Beran, Milos ^a  

^a NUCLEAR PHYSICS INSTITUTE   (Czech Republic)

Author keywords

177Lu; Monoclonal antibody; Nimotuzumab; Radioimmunotherapy

Indexed keywords

2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE TETRAACETIC ACID; 2 (4 ISOTHIOCYANATOBENZYL)DIETHYLENETRIAMINE PENTAACETIC ACID; ANTINEOPLASTIC AGENT; CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; NIMOTUZUMAB LU 177; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL LINE; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; RECEPTOR BINDING; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; LUTETIUM; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION;

EID: 84855317387     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.07.001     Document Type: Article

References (51)

1. Schaefer N.G., Ma J., Huang P., Buchanan J., Wahl R.L. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med 2010, 51(6):987-994.
2. Sharkey R.M., Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005, 46(Suppl 1):115S-127S.
3. Govindan SVG, David M Immunoconjugate anticancer therapeutics. Discovery 2010, 371-392.
4. Mendelsohn J., Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006, 33(4):369-385.
5. Rocha-Lima C.M., Soares H.P., Raez L.E., Singal R. EGFR targeting of solid tumors. Cancer Control 2007, 14(3):295-304.
6. Carpenter G., Cohen S. Epidermal growth factor. Annu Rev Biochem 1979, 48:193-216.
7. Real F.X., Rettig W.J., Chesa P.G., Melamed M.R., Old L.J., Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986, 46(9):4726-4731.
8. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002, 29(1 Suppl 4):27-36.
9. Talavera A., Friemann R., Gomez-Puerta S., Martinez-Fleites C., Garrido G., Rabasa A., et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009, 69(14):5851-5859.
10. Martinelli E., De Palma R., Orditura M., De Vita F., Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009, 158(1):1-9.
11. Mateo C., Moreno E., Amour K., Lombardero J., Harris W., Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997, 3(1):71-81.
12. 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nucl Med Commun 2002, 23(12):1155-1164.
13. Allan D.G. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005, 10(9):760-761.
14. Spicer J. Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience. Curr Opin Mol Ther 2005, 7(2):182-191.
15. Bayes M., Rabasseda X., Prous J.R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007, 29(7):467-509.
16. 188Re in adult recurrent high-grade glioma. Cancer Biol Ther 2008, 7(3):333-339.
17. 186Re. J Nucl Med 2004, 45(2):327-337.
18. Ehrhardt G.J., Ketring A.R., Ayers L.M. Reactor-produced radionuclides at the University of Missouri Research Reactor. Appl Radiat Isot 1998, 49(4):295-297.
19. Mausner L.F., Srivastava S.C. Selection of radionuclides for radioimmunotherapy. Med Phys 1993, 20(2 Pt 2):503-509.
20. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 2008, 60(12):1347-1370.
21. Liu S., Edwards D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001, 12(1):7-34.
22. Meares C.F., McCall M.J., Reardan D.T., Goodwin D.A., Diamanti C.I., McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984, 142(1):68-78.
23. Konishi S., Hamacher K., Vallabhajosula S., Kothari P., Bastidas D., Bander N., et al. Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?. Cancer Biother Radiopharm 2004, 19(6):706-715.
24. Stabin M.G., Sparks R.B., Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005, 46(6):1023-1027.
25. 131I-19-iodocholesterol: the pitfalls of using tissue concentration data, the author's reply. J Nucl Med 1975, 16:248-249.
26. Delbeke D. Reaching out with radioimmunotherapy. J Nucl Med 2010, 51(11):16N.
27. Boswell C.A., Brechbiel M.W. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 2007, 34(7):757-778.
28. Ramakrishnan M.S., Eswaraiah A., Crombet T., Piedra P., Saurez G., Iyer H., et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009, 1(1):41-48.
29. Greta Garrido AR, Elias Gracia, Ilia Tikhomirov and Rolando Perez. Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit interaction with the EGFR in renal and epidermal cells. 100th AACR Annual Meeting; Apr 18-22. Denver, CO: In: Proc Am Assoc Cancer Res; 2009. p. Abstract nr 2763.
30. 90Y-DOTA-h-R3. Synthesis and radiolabeling. Nucleus 2007, 41:3-8.
31. 90Y for clinical use. Radiochim Acta 2009, 97(97):739-746.
32. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002, 29(4):431-442.
33. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer. Nucl Med Biol 2010, 37(8):949-955.
34. 90Y-labeled DOTA analogues conjugated to B72.3. Nucl Med Biol 2007, 34(5):493-502.
35. 177Lu-huA33: a radioimmunoconjugate against colorectal cancer. Nucl Med Biol 2006, 33(8):991-998.
36. Zacchetti A., Coliva A., Luison E., Seregni E., Bombardieri E., Giussani A., et al. (177)Lu- labeled MOv18 as compared to (131)I- or (90)Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts. Nucl Med Biol 2009, 36(7):759-770.
37. 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol 1999, 26(3):275-279.
38. Tabrizi M., Tseng C., Roskos L. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11(1-2):81-88.
39. 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol 2006, 33(7):883-889.
40. Pnwar P., Iznaga-Escobar N., Mishra P., Srivastava V., Sharma R.K., Chandra R., et al. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther 2005, 4(8):854-860.
41. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003, 44(1):77-84.
42. Morales A.A., Duconge J., Alvarez-Ruiz D., Becquer-Viart M.L., Nunez-Gandolff G., Fernandez E., et al. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol 2000, 27(2):199-206.
43. 111In for imaging human breast cancer. J Nucl Med 2000, 41(5):903-911.
44. Wen X., Wu Q.P., Ke S., Ellis L., Charnsangavej C., Delpassand A.S., et al. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225. J Nucl Med 2001, 42(10):1530-1537.
45. 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther 2010, 9(8):2297-2308.
46. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother 2005, 54(12):1200-1213.
47. 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol 1998, 25(1):17-23.
48. 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Nucl Med Commun 2008, 29(1):66-75.
49. Zuckier L.S., Berkowitz E.Z., Sattenberg R.J., Zhao Q.H., Deng H.F., Scharff M.D. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 2000, 60(24):7008-7013.
50. Boland W.K., Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009, 9(9):1199-1206.
51. Garrido G., Tikhomirov I.A., Rabasa A., Yang E., Gracia E., Iznaga N., et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 2011, 11(4):373-382.